Circulation-Heart Failure

Article	Citations
Cognitive and Procedural Competencies in the Cardiac Intensive Care Unit	124
Characteristics of United States Counties in Which Heart Failure Clinical Trials of Pharmacotherapy Were Conducted	124
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions	111
Letter by Qiu and Du Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	104
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	99
National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later	82
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	79
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	72
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System	62
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	62
Advanced Life Support Medications in eCPR and the Limits of Causal Inference	60
High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial	58
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes	50
Response by Myte et al to Letter Regarding Article, “Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin”	49
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program	49
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance	49
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion	46
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation	45
Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction	44
Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study	44
Ongoing Enigma of NT-proBNP in HFpEF: Insights From Proteomics	43
Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy	43
Predicted Heart Mass: A Tale of 2 Ventricles	43
Prolonged Extreme Asymptomatic Hypertroponinemia as a Milestone in Diagnosis of Familial Arrhythmogenic Right Ventricular Cardiomyopathy	43
Trajectory of Cognitive Function After Incident Heart Failure	41

Letter by Baldovino et al Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	41
Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock	38
Rethinking the Nomenclature of Heart Failure Cardiogenic Shock: Do We Need to Start De Novo?	38
Incidence and Outcomes of Advanced Heart Failure in Adults With Congenital Heart Disease	36
Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study	35
Rethinking Donor and Recipient Risk Matching in Europe and North America: Using Heart Transplant Predictors of Donor and Recipient Risk	35
Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death	35
Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study	34
Expanding the Lens on Heart Failure Risk Stratification	33
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	32
Real-Time Biventricular Pressure-Volume Loops During Percutaneous Pulmonary Valve Implantation in Patients With RVOT Dysfunction	32
Mechanisms Behind Dyspnea in Preload Insufficiency	32
Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications	31
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State	31
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity	31
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark	30
Peripheral Venous Pressure+Fenestration Doppler=Noninvasive Cardiac Catheterization Post-Fontan	30
Letter by Hu Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	30
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure	30
Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation	30
Response by Prisco and Prins to Letter Regarding Article, “Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventri	29
Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?	29
Pressure Overload–Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone Apc Min Mice	29
Knowing All the Angles (on Right Ventricular Myocardial Remodeling)	29
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis	29
Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1	29
Easing the Strain: Atrial Function After Atrial Shunting	29
Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction	28
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury	28
Letter by Lim Regarding Article, “The Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the Danger Shock Trial?”	27
Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay	27
Cardiomyopathy Across the Tree of Life: Insights for Clinicians and Investigators	27
Markets, Messaging, and Mastery: Reframing the Conversation Around the Heart Failure Physician Workforce	27
Mucopolysaccharidosis Type IIIA Presenting as Hypertrophic Cardiomyopathy	26
Will the SGLT2i Responders Please Stand Up?	26
Letter by Kounis et al Regarding Article, “Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine”	26
Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure	25
Response by Ezekowitz to Letter Regarding Article, “Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction”	24
Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea	24
Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry	23
Air Pollution and Exposomic Impacts on Heart Failure	23
PHM in Heart Transplantation: From Predicted Heart Mass to Practical Heart Matching	23
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF	22
Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality	22
SCAI Stage B Cardiogenic Shock: Beginning, Bad, and Broad?	22
Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis	22
Single Arterial Access for VA-ECMO–Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve	21
Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction	21
Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF	21
Race, Sex, and Age Disparities in the Performance of ECG Deep Learning Models Predicting Heart Failure	21

Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial	21
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF	21
Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry	20
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure	20
A Sweet Solution for Heart Failure With Preserved Ejection Fraction: The Role of Sodium-Glucose Cotransporter-2 Inhibitors	20
Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study	20
Phenomapping of Heart Failure Patients: All Clusters Are Wrong, But Are They Useful?	20
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure	19
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock	19
Cardiorenal Syndrome: An Evolutionary Appraisal	19
Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin	19
Defining the Specific Skeletal Muscle Adaptations Responsible for Exercise Training Improvements in Heart Failure With Preserved Ejection Fraction	19
SGLT2 Inhibitor–Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event	19
Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations	19
NETosis Is an Important Component of Chronic Myocardial Inflammation in Patients With Heart Failure	19
Unraveling the Pathophysiological Mechanisms of Phospholamban R14del Cardiomyopathy: A Comprehensive Overview	19
Response by Schlender et al to Letter Regarding Article, “Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support”	19
Transfer to Hub Hospitals and Outcomes in Cardiogenic Shock	18
Comparison of Blood Volume Profiles in Heart Failure With Preserved and Reduced Ejection Fractions: Sex Makes a Difference	18
Center and Geographic Variability in Acceptance of the First Donor Heart by Race	18
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF	18
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure	18
SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure	17
Patient Perceptions and Knowledge Surrounding Pregnancy After Heart Transplantation: A Multicenter Study	17
Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation	17
Pulmonary Artery Pressure-Guided Heart Failure Management Reduces Hospitalizations in Patients With Chronic Kidney Disease	17
Single-Nuclei Transcriptomic Profiling of Human Myocardium in Long-Chain 3-Hydroxyacyl-Coenzyme A Dehydrogenase Deficiency	17
Sex-Associated Differences in the Clinical Outcomes of Left Ventricular Assist Device Recipients: Insights From Interagency Registry for Mechanically Assisted Circulatory Support	17
Racial and Social Vulnerability Hotspots in Premature Heart Failure Mortality Across US Counties	17
Improving Fairness in the Prediction of Heart Failure Length of Stay and Mortality by Integrating Social Determinants of Health	17
Response by Baudry et al to Letter Regarding Article, “Sex-Related Prognosis of VA-ECMO-Treated Cardiogenic Shock: A Post Hoc Analysis of the HYPO-ECMO Trial”	16
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial	16
Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction	16
Succinylation of SERCA2a at K352 Promotes Its Ubiquitinoylation and Degradation by Proteasomes in Sepsis-Induced Heart Dysfunction	16
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update	16
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF	16
Are Men and Women That Different?	16
Arterial Versus Mixed Venous Lactate Levels in 1526 Cardiac Intensive Care Patients	16
Integrative Multiomics for Prognostic Assessment in Pulmonary Arterial Hypertension	15
Outcomes of Combined Heart and Kidney Transplantation Under the New Heart Allocation Policy: A United Organ Network for Organ Sharing Database Analysis	15
Nitric Oxide–Mediated Coronary Endothelial Function Is Impaired in Patients With Heart Failure With Preserved Ejection Fraction	15
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing	15
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial	15
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity	15
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial	15
Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care	15
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy	15
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction	14
Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction	14
Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy	14
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease	14
Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score	14
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	14
Beneath the Surface: Unraveling the Proteomics of Diabetes-Related Heart Failure	14
Conceptualizing Liberation From Venoarterial Extracorporeal Membrane Oxygenation	13
Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices	13
Combined Loss of Obsc and Obsl1 in Murine Hearts Results in Diastolic Dysfunction, Altered Metabolism, and Deregulated Mitophagy	13
Precision Medicine Is in the Eye of the Beholder	13
Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant	13
Abnormal Left Atrial Strain by CMR Is Associated With Left Heart Disease in Patients With Pulmonary Hypertension	13
Treatment With Myosin Inhibitor in a Patient With Symptomatic Hypertrophic Cardiomyopathy With Isolated Right Ventricular Obstruction	13
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF	13
Response by Park et al to Letter Regarding Article, “Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to	13
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease	12
Letter by Xiong and Xie Regarding Article, “TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension”	12
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction	12
Letter by ten Berg et al Regarding Article, “Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Regis	12
Building Resilient Clinicians: Lessons From Palliative Care Training for the Heart Failure Community	12
Letter by Shah Regarding Article, “Reversible Cause of Heart Failure?”	12
Impact of Heart Transplant Allocation Change on Waitlist Mortality and Posttransplant Mortality in Patients With Left Ventricular Assist Devices	12
Letter by Sun et al Regarding Article, “Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction”	12
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction	11
Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support	11
Response by Reddy to Letter Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	11
Right Ventricular Function, Inflammation, and the Gut Microbiome in Pulmonary Hypertension: A Translational Frontier	11
You Are Where You Eat: The Local Environment and Risk of Heart Failure	11
Response by Jentzer et al to Letters Regarding Article, “Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock”	11
Changes in Heart Transplant Listings by Insurance and Race During the COVID Public Health Emergency	11
From Signal to Surveillance: Assessing the Role of MicroRNAs in Cardiac Allograft Rejection	11
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study	11

Response by Glargaard et al to Letter Regarding Article, “Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure”	11
Acute Heart Failure Caused by Rupture of Sinus of Valsalva Into Right Atrium in a Patient With Possible Infective Endocarditis After Tricuspid Annuloplasty: A Misdirected Clinical Decision-Making	11
Patients Who Donate Biospecimens for Research Leave a Valuable and Underappreciated Scientific Legacy	10
Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy	10
Letter by Wei et al Regarding Article, “Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin”	10
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study	10
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial	10
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome	10
Second Wave: Dynamic LVOT Obstruction in a Patient With Previous Subaortic Membrane	10
Pathological Analysis of T1 Pseudonormalization in the Advanced Stage of Female Fabry Cardiomyopathy	10
Continuous-Flow Intra-Aortic Percutaneous Mechanical Circulatory Support in Heart Failure With Worsening Renal Function	10
Michael R. Bristow: The Consummate Physician-Scientist of This Generation	10
Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals	9
Long-Term Trajectories of Left Heart Geometry, Mechanics, and Oxygen Demand After Bariatric Surgery	9
Reframing the Cytokine Hypothesis: Lessons Learned From Clonal Hematopoiesis	9
Prolonged Biventricular Berlin Heart EXCOR Support as a Bridge to Heart Transplantation in an Infant: The Victory of Little Warrior	9
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry	9
Correction to: Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction	9
TAVI With ACURATE neo2 Valve in Aortic Regurgitation Due to Left Ventricular Assist Device: A Custom-Made Option	9
Can Exercise and Behavioral Therapy Mend a Broken Heart?	9
Association of Lifestyle With Incidence of Heart Failure According to Metabolic and Genetic Risk Status: A Population-Based Prospective Study	9
Combining Minimally Invasive Surgery With Ultra-Fast-Track Anesthesia in HeartMate 3 Patients: A Pilot Study	9
Atrial Septal Defect, Pulmonary Arterial Hypertension, and Diastolic Left Heart Failure: When 3 Players Come into the Game	9
Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial	9
Editors and Editorial Board	9
Response by Shah et al to Letter Regarding Article, “False-Positive 99m Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy”	9
Epidemiology and Outcomes of Aortic Stenosis in Acute Decompensated Heart Failure: The ARIC Study	9
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study	9
Transfusions in Heart Failure and Acute Myocardial Infarction: Novel Data Begets New Questions	9
Musclin and HFpEF: Unlocking Skeletal Muscle Potential to Improve Exercise Tolerance	9
Significance of Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Negative Endomyocardial Biopsies: A Dawn of a New Era	9
First In-Man Experience With TricValve Transcatheter Bicaval Valve System in Left Ventricular Assist Device Heartmate II Patient for High-Risk Tricuspid Regurgitation	9